Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Motus GI Holdings launches mobile app for on-demand support » 08:10
06/15/20
06/15
08:10
06/15/20
08:10
MOTS

Motus GI Holdings

$1.15 /

-0.03 (-2.54%)

Motus GI Holdings…

Motus GI Holdings announced that physicians and hospitals using the Pure-Vu System will now have on-demand access to a full spectrum of Motus support and educational resources via the new Motus GI mobile app, which was launched today. This new mobile solution is a part of a larger effort to diversify and digitize much of the go-to-market content for the Pure-Vu System, which is being adopted by a growing number of major U.S. hospitals since being commercially launched at the end of 2019. This new mobile interface provides Pure-Vu System users instant access to on-demand video support and training resources, including demo and intra-procedural videos, live set-up tutorials, and case studies. The app can be customized to individual hospitals, enabling the administration and healthcare teams to share and track protocols and upload external materials specific to their respective endoscopy department. It is available to all Pure-Vu System users via the 'imsmart' umbrella in the App store. The Pure-Vu System is designed to improve visualization of the colon, enabling gastroenterologists to perform a quality colonoscopy. The system is cleared for use by the U.S. Food and Drug Administration to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The system integrates with standard and slim colonoscopes to improve visualization during a colonoscopy, while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. Challenges with bowel preparation for inpatient colonoscopy, particularly patients who are elderly, with comorbidities, or active bleeds, represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care. Motus GI believes the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon for a quality exam. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen. Motus GI estimates that approximately four million inpatient colonoscopy procedures take place worldwide each year.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$1.15 /

-0.03 (-2.54%)

MOTS Motus GI Holdings
$1.15 /

-0.03 (-2.54%)

04/21/20
Fly Intel: Top five analyst initiations
04/21/20 H.C. Wainwright
Motus GI Holdings initiated with a Buy at H.C. Wainwright
03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
MOTS Motus GI Holdings
$1.15 /

-0.03 (-2.54%)

Over a month ago
Earnings
Motus GI Holdings reports Q1 EPS (23c), consensus (22c) » 16:17
05/14/20
05/14
16:17
05/14/20
16:17
MOTS

Motus GI Holdings

$1.11 /

+0.005 (+0.45%)

The Company reported…

The Company reported approximately $21.5 million in cash, cash equivalents and investments as of March 31, 2020, compared to $15.3 million for the same period of 2019. The Company believes its cash, cash equivalents and investments will be sufficient to ensure compliance with the Silicon Valley Bank liquidity covenant into late fourth quarter 2020 and meet its anticipated cash requirements into 2021. "Our commercialization strategy for the Pure-Vu(R) System, which is focused on building a strong foundation of leading U.S. hospital systems, continues to build positive momentum with additional placements and evaluations in the first quarter of 2020. We believe that driving adoption and utilization at these prominent national and regional hospitals will provide the reference centers needed to expand our footprint more broadly," stated Tim Moran, Chief Executive Officer of Motus GI. "While we are faced with unprecedented market challenges associated with the COVID-19 pandemic, including restricted access to hospitals and social distancing guidelines, we have developed remote sales and clinical support capabilities that keep us in active contact with our customers and allow us to engage new hospitals. One of the biggest impacts to the market has been a drop in the number of inpatient colonoscopies performed, as hospitals deferred procedures due to the risks associated with the COVID-19 pandemic. We are now preparing to support our customers as they slowly begin to reactivate their GI labs. For these patients, ensuring the avoidance of unnecessary delays or hospitalizations will be critical and we believe our Pure-Vu System may allow for a successful procedure the first time by improving visualization in patients with poorly prepared colons."

ShowHide Related Items >><<
MOTS Motus GI Holdings
$1.11 /

+0.005 (+0.45%)

MOTS Motus GI Holdings
$1.11 /

+0.005 (+0.45%)

04/21/20
Fly Intel: Top five analyst initiations
04/21/20 H.C. Wainwright
Motus GI Holdings initiated with a Buy at H.C. Wainwright
03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
MOTS Motus GI Holdings
$1.11 /

+0.005 (+0.45%)

Hot Stocks
Motus GI Holdings announces patent for Pure-Vu System's sensing technology » 08:42
05/05/20
05/05
08:42
05/05/20
08:42
MOTS

Motus GI Holdings

$1.12 /

+0.07 (+6.67%)

Motus GI Holdings…

Motus GI Holdings announced that the U.S. Patent and Trademark Office has issued patent No. 10646108 titled "Ancillary vacuum module usable with an endoscope", which protects the Company's flagship product - the Pure-Vu System. The patent covers the integration of Motus GI's proprietary sensing technology and enhanced suction systems with a colonoscope's working channel. The Pure-Vu System is cleared by the U.S. Food and Drug Administration to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. Challenges with bowel preparation for inpatient colonoscopy, particularly patients who are elderly, with comorbidities, or active bleeds, represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care. Motus GI believes the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon, which we believe may lead to a quality exam the first time. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen. Motus GI estimates that approximately four million inpatient colonoscopy procedures take place worldwide each year.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$1.12 /

+0.07 (+6.67%)

04/21/20
Fly Intel: Top five analyst initiations
04/21/20 H.C. Wainwright
Motus GI Holdings initiated with a Buy at H.C. Wainwright
03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
Initiation
Fly Intel: Top five analyst initiations » 10:07
04/21/20
04/21
10:07
04/21/20
10:07
LYFT

Lyft

$30.05 /

-0.05 (-0.17%)

, APRE

Aprea Therapeutics

$33.32 /

+0.32 (+0.97%)

, SHAK

Shake Shack

$46.74 /

+0.35 (+0.75%)

, DS

Drive Shack

$1.15 /

+0.03 (+2.68%)

, MOTS

Motus GI Holdings

$0.65 /

-0.02 (-2.99%)

, PLAN

Anaplan

$36.88 /

-0.71 (-1.89%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Buy at Argus. 2. Aprea Therapeutics (APRE) initiated with an Outperform at Baird. 3. Shake Shack (SHAK) initiated with a Neutral at BTIG. 4. Drive Shack (DS) initiated with a Buy at BTIG. 5. Motus GI Holdings (MOTS) initiated with a Buy at H.C. Wainwright. 5. Anaplan (PLAN) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
LYFT Lyft
$30.05 /

-0.05 (-0.17%)

04/21/20 Guggenheim
Guggenheim raises two auto parts retailers, cuts one supplier in sector shake-up
04/21/20 Argus
Lyft initiated with a Buy at Argus
04/20/20 Barclays
Barclays recommends buying Uber and Lyft before recovery 'becomes obvious'
04/03/20 Goldman Sachs
Lyft price target lowered to $37 from $64 at Goldman Sachs
APRE Aprea Therapeutics
$33.32 /

+0.32 (+0.97%)

04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
04/20/20 Baird
Aprea Therapeutics initiated with an Outperform at Baird
10/28/19 RBC Capital
Aprea Therapeutics initiated with an Outperform at RBC Capital
10/28/19 Morgan Stanley
Aprea Therapeutics initiated with an Equal Weight at Morgan Stanley
SHAK Shake Shack
$46.74 /

+0.35 (+0.75%)

04/21/20 SunTrust
Shake Shack price target raised to $50 from $43 at SunTrust
04/20/20 BTIG
Shake Shack initiated with a Neutral at BTIG
04/20/20 BTIG
Shake Shack initiated with a Neutral at BTIG
04/06/20 JPMorgan
Shake Shack price target lowered to $40 from $59 at JPMorgan
DS Drive Shack
$1.15 /

+0.03 (+2.68%)

04/20/20 BTIG
Drive Shack initiated with a Buy at BTIG
04/20/20 BTIG
Drive Shack initiated with a Buy at BTIG
10/15/19
Fly Intel: Top five analyst initiations
10/15/19 JMP Securities
Drive Shack initiated with an Outperform at JMP Securities
MOTS Motus GI Holdings
$0.65 /

-0.02 (-2.99%)

04/21/20 H.C. Wainwright
Motus GI Holdings initiated with a Buy at H.C. Wainwright
03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
PLAN Anaplan
$36.88 /

-0.71 (-1.89%)

04/21/20 Deutsche Bank
Anaplan initiated with a Buy at Deutsche Bank
04/16/20 Rosenblatt
Anaplan downgraded to Neutral from Buy at Rosenblatt
04/13/20 Needham
Needham cuts price targets across SaaS/Application Software names
02/28/20 SunTrust
Anaplan price target lowered to $53 from $68 at SunTrust
Initiation
Motus GI Holdings initiated with a Buy at H.C. Wainwright » 07:06
04/21/20
04/21
07:06
04/21/20
07:06
MOTS

Motus GI Holdings

$0.67 /

-0.02 (-2.90%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen initiated coverage of Motus GI Holdings with a Buy rating and $3 price target. Motus is an emerging medical technology company with a platform aimed at enhancing the efficiency and accuracy of colonoscopies, Chen tells investors in a research note. The analyst believes the company's platform should see broad deployment within the gastrointestinal niche over the coming years.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$0.67 /

-0.02 (-2.90%)

03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
Hot Stocks
Motus GI Holdings receives approval for GEN2 Pure-Vu system in Israel » 09:18
04/07/20
04/07
09:18
04/07/20
09:18
MOTS

Motus GI Holdings

$0.61 /

-0.0192 (-3.05%)

Motus GI Holdings…

Motus GI Holdings announced it has received approval from the Israeli Ministry of Health, Medical Device Division to initiate commercial sales of the GEN2 Pure-Vu System in Israel. This regulatory clearance gives Motus GI access to the Israeli medical device market - one of the largest in the Middle East. The Pure-Vu System is cleared by the U.S. Food and Drug Administration to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care. Motus GI believes the Pure-Vu System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and improve visualization enhancing the quality of an exam. In multiple clinical studies to date, involving challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than 95% following a reduced prep regimen.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$0.61 /

-0.0192 (-3.05%)

03/30/20 Piper Sandler
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler
06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
Over a quarter ago
Recommendations
Motus GI Holdings price target lowered to $3 from $4 at Piper Sandler » 20:43
03/30/20
03/30
20:43
03/30/20
20:43
MOTS

Motus GI Holdings

$0.67 /

-0.03 (-4.29%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Motus GI Holdings to $3 from $4 and keeps an Overweight rating on the shares. The analyst notes that the company continues to see significant interest in Pure-Vu as it continues to pursue a "focused key account strategy", but because of COVID-19, he sees some elongation in its sales cycle. Accordingly, O'Brien notes that Motus is taking cost containment steps to reduce its cash burn, though he sees the company on solid footing financially.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$0.67 /

-0.03 (-4.29%)

06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
Earnings
Motus GI Holdings reports Q4 EPS (21c), consensus (21c) » 16:10
03/30/20
03/30
16:10
03/30/20
16:10
MOTS

Motus GI Holdings

$0.67 /

-0.03 (-4.29%)

The Company reported…

The Company reported approximately $28.7 million in cash, cash equivalents and investments as of December 31, 2019. Following implementation of the outlined reduction plan, the Company believes its cash, cash equivalents and short-term investments will be sufficient to ensure compliance with the SVB liquidity covenant into late fourth quarter 2020 and meet its anticipated cash requirements into 2021."I am pleased with our commercial progress since launching the Pure-Vu(R) System just last quarter. Our team is executing upon the key directives we set out at the start of this program in October. As a result, the Pure-Vu(R) System is now being utilized at several of the top ranked GI hospitals in the US, all of which were in our original targeting plan," stated Tim Moran, Chief Executive Officer of Motus GI. "To date, we've received positive feedback from early-adopter hospitals and garnered increased industry attention for the Pure-Vu(R) System. Establishing an early foothold among key institutions and prominent physicians in the GI space is in line with our go-to-market strategy, which we expect, over time, will allow for broader utilization and adoption of the Pure-Vu(R) System." "Our team has already trained over 50 GIs at more than 15 major hospitals on the Pure-Vu(R) System, with the earliest hospitals ramping from two or three physicians to upwards of ten physicians over the past several months. We believe this is just one metric to convey the strong interest in the capabilities of our system and the growing positive word-of-mouth among physicians," said Mr. Moran.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$0.67 /

-0.03 (-4.29%)

06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
Hot Stocks
Motus GI Holdings announces CE Mark approval for GEN2 Pure-Vu System » 09:18
03/27/20
03/27
09:18
03/27/20
09:18
MOTS

Motus GI Holdings

$0.69 /

+0.0419 (+6.45%)

Motus GI Holdings…

Motus GI Holdings announced receiving CE Mark approval for the GEN2 Pure-Vu System. The company is assessing potential strategic partnership opportunities for the Pure-Vu System with established medical device companies and distributors with commercial operations across the EU.

ShowHide Related Items >><<
MOTS Motus GI Holdings
$0.69 /

+0.0419 (+6.45%)

06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
03/27/19 Piper Sandler
Piper sees 'many catalysts' to move Motus GI shares higher
Earnings
Motus GI Holdings reports Q3 EPS (18c), consensus (25c) » 07:09
11/14/19
11/14
07:09
11/14/19
07:09
MOTS

Motus GI Holdings

$1.77 /

-0.09 (-4.84%)

Reports Q3 revenue…

Reports Q3 revenue $3,000, consensus $20,000. "I am excited by the building momentum of the business as we implement our commercial strategy and continued to deliver on several key milestones in the third quarter, including initiating sales and scaling production of the Pure-Vu(R) System, as well as expanding our U.S. sales team with additional seasoned medical device sales professionals," commented Tim Moran, CEO of Motus GI. "The gastroenterologists and support staff from our initial hospital placements are already reporting positive feedback regarding the Pure-Vu System, along with valuable real-world customer insights that will help us frame our broader U.S. roll-out."

ShowHide Related Items >><<
MOTS Motus GI Holdings
$1.77 /

-0.09 (-4.84%)

06/10/19 Piper Sandler
Motus' Pure Vu system FDA approval sooner than expected, says Piper Jaffray
05/10/19 Piper Sandler
Motus GI Holdings price target lowered to $6 from $8 at Piper Jaffray
03/27/19 Piper Sandler
Piper sees 'many catalysts' to move Motus GI shares higher
02/19/19 Piper Sandler
Piper says Motus GI's growing database of data should help upcoming sales effort

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.